Trial · NCT06316843
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
NCT06316843, Phase 2, Completed, Bateman Horne Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2. Trials, record NCT06316843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06316843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
- NCT number
- NCT06316843
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 59 participants, actual
- Lead sponsor
- Bateman Horne Center
- Conditions
- Long COVID, PASC Post Acute Sequelae of COVID 19
- Interventions
- Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo
- First posted
- 2024-03-19
- Last updated
- 2025-01-22
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fatigue assessed with the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Instrument | 12 weeks | The PROMIS Fatigue 7a will be automatically calculated to a T-score with a standard error of 4. Higher fatigue T-scores represent worse than average fatigue. The primary efficacy analysis will be the mean change from baseline (MCFB) to Week 12 in fatigue based on the weekly survey PROMIS Fatigue 7a T-scores. A mixed models for repeated measures (MMRM) procedure will be used to compare the MCFB between the treatment and placebo arm. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06316843
GET https://conductscience.org/api/trials/v1/NCT06316843/registered